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Abstract
Background: The structural changes of the respiratory system related to ageing determine lung function decline in
healthy subjects after 25 years of age. An annual reduction of 25 ml in Forced Expiratory Volume in 1 s (FEV1) is
expected. We aimed to describe the longitudinal lung function variation of subjects with severe asthma receiving
appropriate treatment.
Methods: Consecutive patients enrolled in a Brazilian reference clinic between 2003 and 2006 were invited to
participate. The study participants were followed up for a median of 8 years, and were evaluated with spirometry in
three distinct occasions (V0, V1 and V8), at least. At V0, upon enrollment, subjects with previous severe untreated
asthma were evaluated by a specialist, had their health resource utilization in the last 12 months recorded, and
performed spirometry. In V1, 1 year after V0, under proper management, subjects repeated the procedures and
answered the Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ). In the last
study visit (V8), 7 years after V1, all patients underwent a pre and post-broncodilator (postBD) spirometry, skin prick
test for aeroallergens, answered the ACQ and the AQLQ and had another interview with the specialist.
Results: Two hundred thirty-four subjects were followed up between V0 and V8. A comparison between
spirometries of V1 and V8, after the initial improvement has supposedly reached a plateau, shows that the FEV1
and FVC declined significantly both in absolute and percent of predicted values. FEV1postBD did not change
significantly between V0 and V1, but declined by −27.1 (−51.1–1.4) ml/yr between V1 and V8.
Conclusions: Currently available treatment with a combination of inhaled corticosteroids and LABA may not be
sufficient to prevent lung function decline in subjects with severe asthma.
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Background
Ageing is associated with reduced chest wall compliance,
impaired respiratory muscle performance and decreased
of lung elastic recoil. The structural alterations of the
respiratory system related to ageing determine lung
function changes of healthy subjects after 25 years old.
An annual reduction of 25 ml in Forced Expiratory
Volume in 1 s (FEV1) is expected in subjects after
25 years of age [1], rising to 38 ml in subjects above
65 years old [2].
Cohort studies of subjects with asthma demonstrated
that the disease can accelerate lung function decline [3, 4].
A baseline FEV1, longer disease duration, ageing and
greater FEV1 variability are related to lung function decline
above the average, among subjects with asthma [5–7].
Longitudinal studies demonstrated that inhaled corti-
costeroids may reduce lung function decline among
adults and children with uncontrolled asthma, especially
if associated with Long Acting Beta 2 Agonist (LABA)
[8–12]. However, most trials had a short follow-up
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period. One retrospective study of subjects with asthma
diagnosed by physician [13] and a prospective study of
subjects with self-reported asthma [14] aimed to evalu-
ate the effect of inhaled corticosteroids on long-term
trends of lung function. Both of these long-term obser-
vational studies indicated that inhaled corticosteroids
reduce the loss in lung function of subjects with asthma,
as compared to subjects not using inhaled corticoste-
roids. A retrospective study of subjects with severe
asthma treated for 10 years indicated that the decline in
FVC is more evident than FEV1, suggesting that small
airway susceptibility may be the cause of rapid disease
progression. Aging, exacerbations of asthma, and use of
systemic corticosteroids were related to excess FVC
decline [15].
However, there remains a gap in the knowledge about
the effect of proper treatment with inhaled corticoste-
roids in the long-term trends of lung function of
subjects with previous untreated severe asthma. It is un-
known whether sustained treatment with high dose of
inhaled corticosteroids can keep lung function decline of
subjects with severe asthma within the physiological
range. The aim of our study was to describe the longitu-
dinal lung function variation of subjects with severe
asthma receiving appropriate treatment with inhaled
corticosteroids and LABA regularly (adherence ≥80 %).
Methods
Study population
Consecutive patients enrolled at the Program for Con-
trol of Asthma in Bahia (ProAR) between 2003 and 2006
were invited to participate. ProAR was established to as-
sist subjects with previous untreated severe asthma from
the Brazilian National Health System (SUS). This Pro-
gram has three components: health care, building cap-
acity and research. All subjects enrolled received
multidisciplinary assistance, underwent spirometry, took
part of an educational program and received free medi-
cation: a combination of an inhaled corticosteroids and a
long acting β2 agonist (LABA), in addition to rescue sal-
butamol spray.
We included subjects with severe asthma according to
the NIH-NHBLI Guidelines for the Diagnosis and
Management of Asthma, 1997 [16] and GINA 2002 cri-
teria [17]. In brief, they had asthma and any one of: (i)
daily or continuous symptoms; (ii) activities limited daily
(symptoms with minor efforts); (iii) nocturnal symp-
toms > 2 times a week; (iv) use of bronchodilators: ≥ 2
times a day; or (v) Peak Expiratory Flow (PEF) or FEV1:
<60 % of predicted. Subjects were not receiving regular
treatment until enrollment, their age was ≥ 12 years old.
Subjects with a smoking history > 9 pack/years, current
smoking, other lung diseases or other conditions that
could possibly interfere in the evaluation of asthma, such
as chronic obstructive pulmonary disease (COPD), tu-
berculosis, heart failure (HF) were not included.
A sample calculation was performed and the size of
sample composed by 171 subjects it should be enough to
achieve a power of 99.8 % to detect differences between
two groups with differences in FEV1 at least of 5.5 %.
The diagnosis of asthma was audited and confirmed
before the last study visit, by two independent special-
ists. The opinion of a third specialist was requested in
case of disagreement about diagnosis or exclusion. For
the validation of asthma diagnosis, we used the clinical
history, previous lung function tests (to confirm variable
airflow obstruction) and chest radiography (to exclude
other lung diseases). All patients were evaluated for the
presence of concomitant chronic rhinitis and other
relevant comorbidities.
The Institutional Review Board of MCO – Federal
University of Bahia, approved the study. All subjects or
their legal guardians signed informed consent.
Study design
This is a prospective real-life analysis of clinical and
functional aspects of a cohort of subjects with previous
untreated severe asthma [18].
The study participants were followed up for a median
of 8 years, and were evaluated with spirometry in three
distinct occasions, at least. Their three main study visits
were titled Visit 0 (V0 – enrollment), Visit 1 (V1 – first
year) and Visit 8 (V8 – final visit). The procedures of
each visit were summarized in Table 1.
Patients had a consultation with a specialist quarterly
for asthma control evaluation and adjustment of the
treatment. They had a pharmacist appointment monthly
for collecting the medication according to their prescrip-
tion and underwent a subjective evaluation of adherence.
The summary of activities developed by patients during
the follow-up is in Table 2.
Assessment tools
Social-demographic and clinical questionnaires
A standardized case report form with socio-demographic
and clinical information was routinely filled out by the
assistent specialist during the first study visit, including
information on age, educational level, age of asthma onset,
rescue medication use, emergence visit need, use of oral
corticosteroid and need for hospitalization due to asthma
in the last 12 months. The information on health resource
utilization and use of oral corticosteroid was collected in
the subsequent study visits as well.
Anthropometric measurements, weight and height
were measured in fasting before the last spirometry, and
the body mass index (BMI) was calculated. Subjects with
BMI ≥ 30 were considered as obese.
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Spirometry
Spirometries were performed before the morning dose
of LABA avoiding use of rescue short acting beta 2
agonists. The last visit was scheduled when there was no
history of exacerbation or acute respiratory infection in
the preceding 4 weeks.
The tests were performed by a trained physiotherapist
with certification by Brazilian Thoracic Society (SBPT),
using a KOKO spirometer (PDS Instrumentation Inc.,
Louisville, CO, EUA), according to the American Thoracic
Society [19] protocol, adopting specific normality stan-
dards for Brazilians [20]. The bronchodilator (Salbutamol
spray 400mcg) reversibility was considered positive when
FEV1 increased at least 200 ml and 12 % from pre-bronch-
odilator (preBD) values [21]. The choice of the best man-
euver was performed manually, only when the test
presented quality A or B [22].
In V0, 195 subjects performed spirometry, but 22
exams were interrupted immediately after the preBD
maneuver because of uncomfortable symptoms. Further
39 preBD tests were not performed because patients
presented an exacerbation or uncomfortable symptoms
on the day scheduled for the test. In V1, 191 patients
performed spirometry. Forty-three subjects could not
perform the test because they had an exacerbation or
acute respiratory infection, and seven patients did the
preBD phase but could not finish the test. In the last
visit (V8), all patients performed a complete spirometry
with pre and post-broncodilator (postBD) phases. One
hundred thirty-nine subjects performed preBD and
postBD tests in V0, V1 and V8.
The period from V0 to V1 was used for stabilization of
symptoms and lung function, with adjustment of the dose
of inhaled corticosteroid for optimization of treatment.
Skin prick test
Immediate-type hypersensitivity skin prick tests were
performed with 14 aeroallergen extracts, on the forearm.
The antigens tested were Alternaria alternata, Aspergil-
lus flavus, Aspergillus niger, Aspergillus fumigatus, Cla-
dosporium herbarum, Dermatophagoides pteronyssinus,
Dermatophagoides farinae, German cockroach, American
cockroach, Cat hair, Dog epithelium, Paspalum notatum,
Cynodon dactilon. (GREER® Labs, EUA) and Blomia
tropicalis (FDA Allergenics, Brazil). As a negative
control, we used saline solution and the positive control
was histamine. The puncture sites were 2 cm apart. The
test was considered positive when at least one antigen
induced a reaction with a diameter ≥ 3 mm greater than
the negative control [23].
Asthma evaluation
The ACQ6 questionnaire was applied to measure asthma
symptoms. It comprises five questions about symptoms
and 1 question about rescue medication. Scores ≥ 1.5 iden-
tify uncontrolled asthma among subjects of our programme
Table 2 Summary of patient’s activities during the follow-up
Activities quarterly Activities monthly Activities annualy
Nurse evaluation (anthropometric data; evaluation and
orientation about correct management of medication)
Specialist consultation (control of asthma evaluation
- GINA; history of health resources use; adjustment of
treatment: step-down or step-up doses by guidelines)
Pharmacist consultation (evaluation of
adherence and correct use of the devices)
Educational meetings (speeches about
knowledge in asthma, its treatment,




Note: GINA global initiative of asthma
Table 1 Outline of procedures at each of the three main study visits
V0 – enrollment V1 - 1 year later V8 – 8 years later
Specialist evaluation with collection
of information on health resource
utilization in the last 12 months
Specialist evaluation Specialist evaluation
Check for inclusion and
non-inclusion criteria
Records of exacerbation history
(emergency visits, hospitalizations
and the use of systemic corticosteroids)
in the last 12 months
Records of exacerbation history
(emergency visits, hospitalizations
and the use of systemic corticosteroids)
in the last 12 months
Evaluation of rhinitis Multidisciplinary approach to
treatment and health education
Multidisciplinary approach to
treatment and health education
Spirometry Spirometry Spirometry
Record of inhaled medications
dispensation (at the beginning)
ACQa Questionnaire ACQa Questionnaire
AQLQb Questionnaire AQLQb Questionnaire
Skin prick test
Note: aAsthma Control Questionnaire (ACQ) [24, 25], bAsthma Quality of Life Questionnaire (AQLQ) [26, 27]
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[24, 25]. The AQLQ questionnaire was applied to evaluate
asthma related quality of life. Higher scores indicate better
quality of life. Score ranges from 0 to 7 [26, 27].
Asthma exacerbations were accounted for every
3 months, at the appointment with the physician. The use
of oral corticosteroids, hospital admissions and emergency
room visits from asthma were carefully noted.
Statistical analysis
The descriptive variables were presented as central and
dispersion tendency measurements: mean, median, stand-
ard deviation, interquartile range. The association between
continuous variables were assessed by means of Wilcoxon
or Friedman Tests, when comparing 2 or 3 visits, respect-
ively. McNemar test was used to verify associations
between categorical variables.
All subjects were evaluated on social, demographic
and clinical characteristics, and the comparison between
visits used all participants. The spirometric measures
were analyzed according to number of subjects that per-
formed preBD (162) and postBD (139) maneuvers in all
study visits.
The data tabulation and analysis was performed using a
software program Statistical Package the Social Sciences
for Windows, 16.0 (SPSS for Windows; SPSS Inc.,
Chicago, IL, USA).
Results
Over the period 2003–2006 we performed 545 screening,
after audit of records we stayed on 306 eligible patients.
We evaluated a total of 236 subjects in the study, however
2 were excluded, one presenting congestive heart failure
diagnosis in the last visit and another because she didn’t
perform any spirometry with good quality (A or B). The
final analysis was performed with 234 subjects and the
inclusion and exclusion of participants was demonstrated
on the flow diagram depicted in Fig. 1. In the enrollment
visit (V0) 192 (82 %) subjects were female, with a median
age of 45 years old, 53 (23 %) were obese, the majority
[199 (85 %)] had associated rhinitis and 131 (56 %) had a
positive skin prick test, at least to 1 allergen.
The median age of asthma onset and of time without
regular treatment was 8 and 30 years, respectively. The
frequency of use of oral corticosteroids and emergency
room visits in the year before admission were (N = 152;
65 %) and (N = 175; 75 %), respectively, due to asthma
exacerbations. Table 3 describes the characteristics of
the study population upon enrollment (V0).
Clinical assessment during the follow up
The 234 subjects were followed up between V0 and V8.
At enrollment in ProAR, a regular inhaled treatment
was started. In the end of the first year of follow up, the
participants had used the combination of formoterol
24mcg/day and an inhaled corticosteroid in a mean dose
equivalent of 813.3 (±247.5) mcg/day of budesonide.
The subjects were reassessed 12 months after starting
the inhaled therapy (V1). We observed a reduction in
the frequency of emergency room visits (−26 %) and the
use of oral corticosteroids (−28 %). The comparison
between V0 and V1 is presented in Table 4.
The final assessment was performed in the end of
eighth year of regular treatment (V8). There was an in-
crease in the mean dose of inhaled corticosteroid (mean
of 1295.5 ± 754.8mcg/day) of budesonide or equivalent
and a further reduction of 17 % in a proportion of emer-
gency visits during the last year of follow up. The
comparison between V1 and V8 is presented in Table 5.
Airflow limitation and BD response at each visit
In V0, 173 complete spirometries were performed (pre
and postBD). One hundred twenty subjects (69.4 %)
presented a FEV1postBD <80 % and a positive BD
response - with improvement ≥ 12 % and 200 ml on
FEV1. Seventy (40.5 %) of them had a FEV1/FVC ratio ≥
0.7 after BD.
In V1, 184 complete tests were performed and assessed.
FEV1 postBD < 80 % was present in 114 (61.6 %) subjects.
Fig. 1 Flow diagram of study inclusion, non inclusion and exclusions.
This flow diagram demonstrates the exclusions in the study during
the follow-up
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Eighty-two (44.3 %) had FEV1/FVC ratio ≥ 0.7 after BD,
and 42 (42.7 %) presented a positive response to BD.
All participants repeated spirometry in the last visit
(V8). One hundred seventy-one (73.1 %) presented
FEV1postBD <80 %. Eighty-eight (37.6 %) had a FEV1/FVC
ratio ≥ 0.7 after BD and 85 (36.3 %) presented a positive
response to BD.
Comparison of lung function between visits
Trends in preBD spirometric parameters
One hundred sixty-two subjects were evaluated preBD
in all three study visits. A statistically significant incre-
ment was observed in all spirometric parameters after
the first year of regular treatment (from V0 to V1).
However, a comparison between spirometric parameters
on V1 and V8, 7 years later, demonstrates a statistically
significant reduction of FEV1 and FVC. The preBD lung
function parameters are depicted in Table 6.
Trends in postBD spirometric parameters
A hundred thirty-nine subjects performed complete lung
function tests (pre and postBD) in all three study visits.
Comparing the measurements enrollment visit (V0) with
the observations after 1 year of regular treatment (V1),
there was a statistically significant increase only in
FEF25–75%, whereas a marked reduction in the response
to bronchodilator was demonstrated (Table 7).
Table 3 Clinical characteristics of all subjects at enrollment (V0)
Characteristics Results
Subjects n 234
Female gender n(%) 192 (82)
Literate patients n(%) 203 (87)
Age in years M(p25-p75) 45 (35–54)
BMI M(p25-p75) 27 (24–31)
BMI≥ 30 n(%) 54 (23)
History of chronic rhinitis n(%) 175 (74)
Positive skin prick test to aeroallergens n(%) 131 (56)
Age of asthma onset (yrs) M(p25-p75) 8 (2–23)
Duration of asthma without treatment (yrs)
M(p25-p75)
30 (18–40)
Any oral corticosteroid requirement in the
year before n(%)
152 (65)
Emergency room visits due to asthma in the
year before (n) M(p25-p75)
4 (2–15)
Proportion of patients that need emergency
room visits due to asthma in the year
before n(%)
175 (75)
Proportion of patients that need ICU
admission due to asthma once n(%)
38 (16)
Proportion of patients that need intubation
due to asthma n(%)
14 (8)
Note: BMI body mass index, ICU intensive care unit, yrs years, n (%) number
(proportion), M(p25-p75) median and interquartile range
Table 4 Clinical characterization from Visit 0 to Visit 1 (all subjects,
n = 234)
Characteristics Visit 0 Visit 1 pa value
Daily dose of inhaled
budesonide equivalent in
the last 3 months (μ ± SD)
b 813.3 (±247.5) -
Use of long acting B2 agonists
associated to inhaled
corticosteroids n(%)
b 200 (86) -
Any oral corticosteroid
requirement in the year
before the visit n(%)
152 (65) 86 (37) <0.01
Number of emergency room
visits due to asthma in the
year before M(p25-p75)
5 (2–15) 0 (0–2) <0.01
Proportion of patients that
need emergency room
visits due to asthma in
the year before n(%)
172 (74) 113 (48) <0.01
Proportion of patients that
need ICU admission due to
asthma in the year before n(%)
19 (9) 2 (1) <0.01
Note: aMcNemar and Wilcoxon Tests. bSubjects were not using regular inhaled
corticosteroids before Visit 1. M(p25-p75) median and interquartile range
Table 5 Clinical changes from Visit 1 to Visit 8 (all subjects, n= 234)
Characteristics Visit 1 Visit 8 pa value





requirement in the year
before n(%)
86 (37) 146 (62) <0.01
Number of emergency
room visits due to
asthma in the year
before M(p25-p75)
0 (0–2) 0 (0–1) <0.01
Proportion of patients
that need emergency
room visits due to asthma
in the year before n(%)
113 (48) 73 (31) <0.01
Proportion of patients
that need ICU admission
due to asthma in the
year before n(%)
2 (1) 4 (2) 0.69
AQLQ scores M(p25-p75) 4 (3–5) 5 (3–6) <0.01
ACQ scores M(p25-p75) 2 (1–3) 1 (0–2) <0.01
Proportion of patients
with ACQ score≥ 1.5 n(%)
141 (60) 87 (37) <0.01
Proportion of patients
with ACQ score≤ 0.75 n(%)
44 (19) 97 (42) <0.01
Note: ACQ asthma control questionnaire, AQLQ asthma quality of life
questionnaire. aMcNemar and Wilcoxon Test
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A comparison between spirometries of V1 and V8,
after the initial improvement has supposedly reached a
plateau, shows that the FEV1 and FVC declined signifi-
cantly both in absolute and percent of predicted values.
FEV1postBD did not change significantly between V0 and
V1, but declined by -27.1 (−51.1–1.4) ml/yr between V1
and V8, using data of all patients with complete spirom-
etry in V1 and V8.
Discussion
Our sample comprised mostly adult subjects with previ-
ous long-standing untreated asthma, characterized by
persistent symptoms, frequent exacerbations and low
lung function. After 1 year of regular treatment with
inhaled corticosteroids and LABA they had a clear
reduction in exacerbations and improvement in lung
function. From the end of the first year of treatment,
which we took as a stable baseline to look at subsequent
lung function decline, to the end of the study period,
7 years later, there was a further reduction in emergency
room visits. However, this was associated with an
increase in the dose of inhaled corticosteroids and the
requirement for oral corticosteroids, based on a written
action plan coupled with a patient education program.
During the 7 years of subsequent regular treatment, we
observed a PreBD decline in FVC, FEV1 and FEF25–75%
in absolute figures. FVC and FEV1 also declined in
percent of predicted values. The PostBD observations,
which are more appropriate to study lung function
decline among subjects with obstructive lung diseases,
confirmed a decline in the absolute figures for FVC,
FEV1 and FEF25–75%. Again, there was also a reduction
in the percent of predicted values for FVC and FEV1.
The median decline of 184 PostBD FEV1 analyzed
was −27.1 (−51.1–1.4) ml/yr between V1 and V8, which is
not far from the average for healthy subjects in this age
range reported from studies in other continents. It is
remarkable that we did not observe any variation in the
PostBD FEV1/FVC ratio during the entire period from the
enrollment to the end of the study, which suggests it is
the least responsive of the spirometric indexes of airway
obstruction. A linear and unidirectional behavior of FEV1
Table 6 Trends in pre-bronchodilator (PreBD) spirometric parameters during follow up
Study visits V0 V1 V8 p valuea p valuea p valueb
(162) (162) (162) V0xV1 V1xV8 V0xV1xV8
FVC (L) 2.5 (2.1–3.2) 2.7 (2.2–3.3) 2.4 (1.9–3.0) <0.01 <0.01 <0.00
FVC (% pred) 82.0 (65.0–94.0) 88.0 (72.0–101.0) 77.1 (67.1–88.0) <0.01 <0.01 <0.00
FEV1 (L) 1.5 (1.2–2.0) 1.8 (1.3–2.2) 1.5 (1.1–2.0) <0.01 <0.01 <0.00
FEV1 (%pred) 59.5 (45–75.8) 66.5 (54.0–82.3) 63.0 (49.4–73.4) <0.01 <0.01 <0.00
FEV1/FVC 0.6 (0.5–0.7) 0.7 (0.5–0.7) 0.7 (0.6–0.7) 0.04 0.69 0.03
FEV1/FVC (%pred) 75.0 (63.8–89.3) 79.0 (64.8–88.0) 80.4 (70.1–88.8) 0.02 0.16 <0.00
FEF25–75% (L/s) 0.5 (0.8–1.3) 0.9 (0.5–1.7) 0.8 (0.6–1.4) <0.01 0.04 <0.01
FEF25–75% (%pred) 27.0 (17.0–48.5) 33.0 (21.0–52.0) 34.5 (24.1–51.0) <0.01 0.19 <0.00
Note: aWilcoxon and bFriedman tests; FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF forced expiratory flow; data presented as median and
interquartile range
Table 7 Trends in post-bronchodilator (PostBD) spirometric parameters during follow up
Study visits V0 V1 V8 p valuea p valuea p valueb
(139) (139) (139) V0xV1 V1x V8 V0xV1xV8
FVC L 2.7 (2.3–3.5) 2.8 (2.3–3.4) 2.6 (2.1–3.1) 0.98 <0.01 0.00
FVC (% pred) 91.0 (77.0–101.0) 91.0(79.0–102.0) 82.2 (73.6–92.0) 0.43 <0.01 0.00
FEV1 (L) 1.9 (1.4–2.3) 1.9 (1.5–2.4) 1.7 (1.3–2.2) 0.41 <0.01 0.00
FEV1 (%pred) 73.0 (60.0–85.0) 73.0 (63.0–86.0) 67.2 (56.3–80.3) 0.15 <0.01 0.00
FEV1/FVC 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.7 (0.6–0.7) 0.34 0.21 0.47
FEV1/FVC (%pred) 82.0 (68.0–93.0) 83.0 (71.0–92.0) 81.5 (74.7–91.4) 0.23 0.41 0.18
FEF25–75% (L/s) 1.0 (0.6–1.6) 1.1 (0.6–1.8) 1.0 (0.7–1.6) 0.04 <0.01 0.05
FEF25–75% (%pred) 34.0 (22.0–57.0) 41.0 (25.0–64.0) 37.8 (29.9–62.7) 0.04 0.88 0.05
BD chg (ml) 290.0(180.0–440.0) 160.0(40.0–340.0) 170.0(70.0–300.0) <0.01 0.87 0.00
BD chg (%) 18.0 (11.0–28.0) 10.0 (2.0–22.0) 11.6 (5.0–20.7) <0.01 0.10 0.00
Note: aWilcoxon and bFriedman tests; FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF forced expiratory flow, BD bronchodilator; data presented
as median and interquartile range
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and FVC during the follow-up, improving in the first year
and decreasing subsequently, could be an alternative
explanation for the relatively sustained FEV1/FVC ratio.
Finally, it is noteworthy that a clear-cut reduction of FEV1
response to bronchodilator was detected after the first
year of treatment and remained the same at the end. We
didn’t find any significant association between change in
FEV1 and response to bronchodilator. We speculate the
reduction in bronchodilator response from V0 to V1 was
likely related to the preBD FEV1 increase, with less room
for dilatation. But this could not be an explanation for the
change from V1 to V8. In this case, we consider the most
likely explanation is a trend towards fixed airway
obstruction.
Our study demonstrated that there is a small decline
in lung function above the physiologic range despite of
increasing dose of inhaled corticosteroids during 7 years
of follow-up after 1 year of stabilization in regular treat-
ment. This is the first estimate, to our knowledge, of
decline in lung function among subjects with long-
standing previously untreated severe asthma, now under
regular and strictly monitored treatment for an extended
follow-up period.
Various studies have demonstrated the benefits of
inhaled corticosteroids to lung function in adults and
children with mild and moderate asthma for periods of
regular treatment up to 3 years [8–10, 12]. Early treat-
ment of asthma seems to be necessary to obtain optimal
benefits of inhaled corticosteroids in lung function [8],
especially in reducing airway remodeling and preventing
fixed airway obstruction [28, 29]. The long-term benefits
of the regular use of inhaled corticosteroid and LABA
combination for subjects with previously untreated
severe asthma, including improvement in lung function,
may surpass the 1 year we decided to adopt as the base-
line plateau to look at the FEV1 postBD decline for prag-
matic reasons. If this assumption is correct, our median
measures of lung function decline express a balance
between some additional improvement, which most
certainly varies widely among subjects, followed by the
true decline. If this speculation is correct the dimension
of the decline is greater than we have measured, thus
favouring our interpretation that there is indeed a
decline above that expected, in spite the treatment with
inhaled corticosteroids.
In our present study, there was an increased in the
long-term utilization of inhaled and oral corticosteroids,
upon medical guidance, with consequent reduced emer-
gency visits. Nevertheless, we have seen a decline in lung
function parameters after 7 years. Clinical improvement
was probably related to reduction of bronchial hyper-
responsiveness due to increasing dose of inhaled cortico-
steroids during follow-up. We did not measure bronchial
hyper-responsiveness but we observed a decrease in the
response to bronchodilator, which may be a proxy of
hyper-responsiveness. A dissociation between symptoms
control and lung function trends was observed in other
studies [30].
Some limitations can be pinpointed in our study. First,
we have no control group of subjects without asthma
from the same specific population. Therefore, lung func-
tion decline was estimated on the basis of predicted
Brazilian values not necessarily similar to our context of
ethnicity mix, socioeconomic and health status. The
majority of our cases were female, over 40 years of age
and overweight. The predominance of women is
expected because asthma is more frequent and severe in
adult females as it was demonstrated in other studies
[31, 32], but our proportion (82 %) was above those of
previous reports from elsewhere. We suspect it might be
influenced by a greater rate of unemployment, which
increases availability for attending medical services
among females, but we have no clear explanation for this
observation yet. This certainly poses a limitation to the
external validity of our findings. We have evaluated the
annual change of FEV1 based in tests performed in V1
and V8. We found our FEV1 change calculation was
acceptable, as it has been often used in the literature
[13, 14, 33]. Nevertheless, we recognize this as a limita-
tion of our study, as it would be better to have extra
points to draw a more precise regression curve.
Although the absolute values of lung function have a
near physiological decline over time, the percent of
predicted values are not expected to decline because
they are already adjusted for age. Therefore we face con-
flicting information: the absolute decline looks is not far
from the normal, but there is a decline in the percent of
predicted too. Standards of lung function normality have
been established for the Brazilians, whereas studies on
lung function decline were never done in the Brazilian
population. Therefore, we consider our interpretation
shall be that we have observed a mild decline over the
average in lung function after 7 years, in spite of regular
treatment including inhaled corticosteroids at high doses
combined with LABA and early intervention with oral
corticosteroids to halt exacerbations, according to a
written action plan.
It is important to continue to follow up this cohort
closely to see the trends as the subjects age. It is crucial also
to dissect lung function decline on an individualized ana-
lysis, rather than looking at the median of the entire group.
We intend to sort out which are the best means to look at
clusters of subjects according to their rate of decline in lung
function and search for determinants of a steeper decline.
Conclusions
We conclude that currently available proper treatment
with a combination of inhaled corticosteroids and LABA
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is not sufficient to prevent lung function decline,
although it improves asthma control and reduces emer-
gency visits, in subjects with previous untreated severe
asthma from under privileged populations in Brazil.
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